Medtronic completes acquisition of CathWorks for $585 million
Medtronic has accomplished its acquisition of CathWorks, an organization specializing in advancing the prognosis and therapy of coronary artery illness (CAD), for $585 million, with additional undisclosed earn-out funds doable following the deal.
The acquisition expands Medtronic’s cardiovascular product portfolio.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra info
In February 2026, the corporate introduced its intention to accumulate CathWorks.
The transfer follows a 2022 strategic partnership and co-promotion settlement for the CathWorks FFrangio system, which is presently commercially out there in Europe, Japan and the US.
The FFRangio system makes use of AI and computational science for the physiological evaluation of the coronary arteries.
The most recent announcement follows the one-year outcomes of CathWorks’ ALL-RISE randomized management trial, shared on the 2026 American School of Cardiology convention.
This trial concerned greater than 1,900 sufferers at 59 websites in Asia, Europe, the Center East and North America.
Medtronic stated the acquisition aligns with its technique to strengthen its place by way of focused mergers and acquisitions and ship long-term worth to its companions within the healthcare business.
It expects the transaction to have minimal influence on fiscal 2027 GAAP and adjusted earnings per share, with outcomes turning impartial or optimistic in subsequent years.
CathWorks President and CEO Ramin Mousavi stated, “With Medtronic’s acquisition of CathWorks, we’re boldly redefining the way forward for cardiovascular care. As I mirror on our long-term partnership, I’m deeply grateful and pleased with what we now have completed collectively.
“This settlement is a testomony to CathWorks and Medtronic’s shared dedication, imaginative and prescient and relentless dedication to revolutionize the catheterization laboratory and ship higher options for sufferers with heart problems. Collectively, we now have ushered in a brand new period in cardiovascular prognosis and affected person outcomes.”
